JP2014508796A - 脂質ナノ粒子とコルチコステロイドまたはビタミンｄ誘導体とを含む組成物 - Google Patents

脂質ナノ粒子とコルチコステロイドまたはビタミンｄ誘導体とを含む組成物 Download PDF

Info

Publication number
JP2014508796A
JP2014508796A JP2014500411A JP2014500411A JP2014508796A JP 2014508796 A JP2014508796 A JP 2014508796A JP 2014500411 A JP2014500411 A JP 2014500411A JP 2014500411 A JP2014500411 A JP 2014500411A JP 2014508796 A JP2014508796 A JP 2014508796A
Authority
JP
Japan
Prior art keywords
lipid
composition
skin
weight
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014500411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508796A5 (enExample
Inventor
ルイーズ・バストルム・イェンセン
カルステン・ペーターソン
Original Assignee
レオ ファーマ アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レオ ファーマ アクティーゼルスカブ filed Critical レオ ファーマ アクティーゼルスカブ
Publication of JP2014508796A publication Critical patent/JP2014508796A/ja
Publication of JP2014508796A5 publication Critical patent/JP2014508796A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014500411A 2011-03-24 2012-03-23 脂質ナノ粒子とコルチコステロイドまたはビタミンｄ誘導体とを含む組成物 Ceased JP2014508796A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467192P 2011-03-24 2011-03-24
US61/467,192 2011-03-24
PCT/EP2012/055222 WO2012127037A2 (en) 2011-03-24 2012-03-23 A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative

Publications (2)

Publication Number Publication Date
JP2014508796A true JP2014508796A (ja) 2014-04-10
JP2014508796A5 JP2014508796A5 (enExample) 2015-04-30

Family

ID=45894467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014500411A Ceased JP2014508796A (ja) 2011-03-24 2012-03-23 脂質ナノ粒子とコルチコステロイドまたはビタミンｄ誘導体とを含む組成物

Country Status (7)

Country Link
US (1) US20140079785A1 (enExample)
EP (1) EP2688560A2 (enExample)
JP (1) JP2014508796A (enExample)
KR (1) KR20140031227A (enExample)
CN (1) CN103442700B (enExample)
RU (1) RU2602171C2 (enExample)
WO (1) WO2012127037A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016166913A1 (ja) * 2015-04-15 2016-10-20 マルホ株式会社 皮膚用の医薬組成物
US10238667B2 (en) 2013-04-24 2019-03-26 Salk Institute For Biological Studies Vitamin D receptor/SMAD genomic circuit gates fibrotic response
JP2019514979A (ja) * 2016-05-09 2019-06-06 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法
JP2022511223A (ja) * 2018-09-11 2022-01-31 リードバイオセラピューティクスリミテッド 粘膜付着性分散ナノ粒子系およびその製造方法
US11376264B2 (en) 2017-07-24 2022-07-05 Salk Institute For Biological Studies Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
SG11201505247TA (en) * 2013-01-14 2015-08-28 Infirst Healthcare Ltd Solid solution compositions and use in cardiovascular disease
WO2014197680A1 (en) 2013-06-05 2014-12-11 Salk Institute For Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
EP2821077A1 (en) * 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
CN103417507B (zh) * 2013-08-23 2015-12-02 王显著 布地奈德药物组合物
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
CZ307681B6 (cs) 2016-02-29 2019-02-13 Ústav makromolekulární chemie AV ČR, v. v. i. Fotoaktivovatelná nanočástice pro fotodynamické aplikace, způsob její přípravy, farmaceutická kompozice ji obsahující a jejich použití
CN106265485A (zh) * 2016-08-22 2017-01-04 江苏知原药业有限公司 一种稳定性改善的卡泊三醇组合物
MX2020006199A (es) * 2017-12-12 2020-08-27 Lead Biotherapeutics Ltd Nanopartícula lípida sólida para liberación intracelular de sustancias activas y método para producción de la misma.
RU2018114533A (ru) * 2018-04-19 2019-10-21 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Композиция на основе твердых липидных частиц, обладающая свойством направленной доставки для лечения вирусных заболеваний (варианты)
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
WO2020231800A1 (en) * 2019-05-10 2020-11-19 Encube Ethicals Private Limited Topical antifungal formulation
EP3741378A1 (de) 2019-05-23 2020-11-25 Dimitrios Tsakouridis Zusammensetzung zur topischen behandlung und pflege der psoriatischen haut
CN111588696A (zh) * 2020-04-28 2020-08-28 南通华山药业有限公司 一种阿法骨化醇口服脂质体药物及其制备方法与应用
CN111494321A (zh) * 2020-04-28 2020-08-07 南通华山药业有限公司 一种骨化三醇长循环脂质体及其制备方法
WO2021232054A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Compositions for treating hair loss
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза
WO2022203145A1 (ko) * 2021-03-22 2022-09-29 주식회사 앱스바이오 매스틱검 또는 감마오리자놀로 제조한 지질나노입자 조성물
JP7633712B2 (ja) * 2023-05-12 2025-02-20 アピ株式会社 外用組成物
KR102725138B1 (ko) * 2023-10-30 2024-11-05 김윤영 나노비타민 복합 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044617A1 (fr) * 1998-03-04 1999-09-10 Teijin Limited Lotions de vitamines d3 activees sous forme d'emulsion
JP2011504870A (ja) * 2006-11-30 2011-02-17 ガルデルマ・ソシエテ・アノニム ビタミンｄ誘導体および任意にステロイド系抗炎症剤を含む、ワセリンフリーの軟膏形態にある新規組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658608B2 (en) * 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
DE4131562A1 (de) 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
US5763426A (en) 1993-01-15 1998-06-09 Leo Pharmaceutical Products Ltd. Crystalline form of a vitamin D analogue
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
AU4917900A (en) * 1999-05-07 2000-11-21 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US7147841B2 (en) * 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
EP1912679A4 (en) * 2005-06-15 2009-07-29 Massachusetts Inst Technology AMINOUS LIPIDS AND ITS USES
FR2893847B1 (fr) * 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un derive de vitamine d et une phase huileuse
US20080064669A1 (en) * 2006-08-29 2008-03-13 Rakefet Cohen Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
US8470304B2 (en) * 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044617A1 (fr) * 1998-03-04 1999-09-10 Teijin Limited Lotions de vitamines d3 activees sous forme d'emulsion
JP2011504870A (ja) * 2006-11-30 2011-02-17 ガルデルマ・ソシエテ・アノニム ビタミンｄ誘導体および任意にステロイド系抗炎症剤を含む、ワセリンフリーの軟膏形態にある新規組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R. SIVARAMAKRISHNAN ET AL.: " Glucocorticoid entrapment into lipid carriers − characterisation by parelectric spectroscopy and i", JOURNAL OF CONTROLLED RELEASE, vol. 97, no. 3, JPN6015053023, 2004, pages 493 - 502, ISSN: 0003230269 *
ZHANG, JIN ET AL.: "Percutaneous Permeation of Betamethasone 17-ValerateIncorporated in Lipid Nanoparticles", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 100, no. 3, JPN6015053024, 2011, pages 896 - 903, ISSN: 0003230270 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238667B2 (en) 2013-04-24 2019-03-26 Salk Institute For Biological Studies Vitamin D receptor/SMAD genomic circuit gates fibrotic response
WO2016166913A1 (ja) * 2015-04-15 2016-10-20 マルホ株式会社 皮膚用の医薬組成物
JP2019514979A (ja) * 2016-05-09 2019-06-06 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法
JP7066632B2 (ja) 2016-05-09 2022-05-13 アストラゼネカ・アクチエボラーグ 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法
US11376264B2 (en) 2017-07-24 2022-07-05 Salk Institute For Biological Studies Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment
JP2022511223A (ja) * 2018-09-11 2022-01-31 リードバイオセラピューティクスリミテッド 粘膜付着性分散ナノ粒子系およびその製造方法
JP7164700B2 (ja) 2018-09-11 2022-11-01 リードバイオセラピューティクスリミテッド 粘膜付着性分散ナノ粒子系およびその製造方法

Also Published As

Publication number Publication date
WO2012127037A3 (en) 2012-12-27
WO2012127037A2 (en) 2012-09-27
RU2602171C2 (ru) 2016-11-10
CN103442700B (zh) 2016-04-06
EP2688560A2 (en) 2014-01-29
US20140079785A1 (en) 2014-03-20
RU2013147429A (ru) 2015-04-27
KR20140031227A (ko) 2014-03-12
CN103442700A (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
RU2602171C2 (ru) Композиция, содержащая липидные наночастицы и кортикостероид или производное витамина d
Kandekar et al. Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers
Cevc et al. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage
Jensen et al. In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin
JP7250689B2 (ja) 活性化合物のための局所送達系
KR101930246B1 (ko) 국소용 코르티코스테로이드 조성물
CN102781425B (zh) 含有维生素d类似物以及溶剂和表面活性剂混合物的皮肤用组合物
EP1915133A1 (fr) Émulsion de type huile-dans-eau pour application topique en dermatologie
UA125500C2 (uk) Фармацевтичні композиції для місцевого застосування
Contreras et al. In vitro percutaneous absorption of all-trans retinoic acid applied in free form or encapsulated in stratum corneum lipid liposomes
Salau et al. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats
AU2010335655B2 (en) Calcipotriol monohydrate nanocrystals
Şenyiğit et al. Deoxycholate hydrogels of betamethasone-17-valerate intended for topical use: in vitro and in vivo evaluation
KR20230011997A (ko) 모낭으로 생물활성제를 전달하기 위한 조성물
Kakade et al. Formulation development of nanostructured lipid carrier-based nanogels encapsulating tacrolimus for sustained therapy of psoriasis
JP2023139134A (ja) 皮膚疾患を治療するためのフェノルドパム局所製剤
US10342774B2 (en) Topical pharmaceutical composition of acitretin
WO2020172333A1 (en) Method for therapeutic treatment of rosacea
EP4169512A1 (fr) Composition dermatologique comprenant des oléosomes et des rétinoïdes, son procédé de préparation et son utilisation
Vejjabhinanta et al. Fluocinolone acetonide microemulsion in combination with a fractional laser for the treatment of scalp psoriasis
US11197831B2 (en) Compositions comprising at least one dispersed active principle and lipid microcapsules
Wiedersberg Dermatopharmacokinetics and pharmacodynamics of topical glucocorticoids
HK1177899B (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
CN107530362A (zh) 皮肤用的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170530

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170926